Last reviewed · How we verify
GVGH Shigella sonnei 1790GAHB vaccine
GVGH Shigella sonnei 1790GAHB vaccine is a Biologic drug developed by GlaxoSmithKline. It is currently in Phase 1 development.
At a glance
| Generic name | GVGH Shigella sonnei 1790GAHB vaccine |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Efficacy, Safety and Immunogenicity of a Vaccine Designed to Protect Against Infection With Shigella Sonnei in Healthy Adults (PHASE2)
- A Study to Evaluate Safety and Immunogenicity of 1 Booster Dose of 1790GAHB Vaccine in Healthy Adults Primed With 3 Doses of 1790GAHB Vaccine in Study H03_01TP Compared to 1 Vaccination of 1790GAHB in Either Subjects Who Received Placebo in the Same Study or naïve Subjects Not Part of H03_01TP Study (PHASE1)
- A Study of the Safety and Immune Response of 2 Doses of a New Shigella Vaccine in Kenyan Adults (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GVGH Shigella sonnei 1790GAHB vaccine CI brief — competitive landscape report
- GVGH Shigella sonnei 1790GAHB vaccine updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI
Frequently asked questions about GVGH Shigella sonnei 1790GAHB vaccine
What is GVGH Shigella sonnei 1790GAHB vaccine?
GVGH Shigella sonnei 1790GAHB vaccine is a Biologic drug developed by GlaxoSmithKline.
Who makes GVGH Shigella sonnei 1790GAHB vaccine?
GVGH Shigella sonnei 1790GAHB vaccine is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).
What development phase is GVGH Shigella sonnei 1790GAHB vaccine in?
GVGH Shigella sonnei 1790GAHB vaccine is in Phase 1.